Poor
Non-Aligned
Patient Risk:
Low
Summary
Most extracted claims are absent from the provided label text, and the remaining claims about strengths are only partially supported because the label evidence does not explicitly state that the API is clonazepam hydrochloride or define potency measurement concepts. Manufacturing/QC/testing method and regulatory compliance claims are not supported by the provided label sections.
Category Scores
Accurate Statements
Aurobindo's clonazepam tablets contain 0.5 mg of clonazepam hydrochloride per tablet.
Partially supported by the provided DESCRIPTION section stating availability of scored tablets containing 0.5 mg of clonazepam; the provided evidence does not explicitly state the formulation as 'clonazepam hydrochloride.'
Aurobindo's clonazepam tablets contain 1 mg of clonazepam hydrochloride per tablet.
Partially supported by the provided DESCRIPTION section stating unscored tablets containing 1 mg of clonazepam; the provided evidence does not explicitly state the formulation as 'clonazepam hydrochloride.'
Aurobindo's clonazepam tablets contain 2 mg of clonazepam hydrochloride per tablet.
Partially supported by the provided DESCRIPTION section stating unscored tablets containing 2 mg of clonazepam; the provided evidence does not explicitly state the formulation as 'clonazepam hydrochloride.'
Unsupported Statements
Clonazepam is an anxiolytic medication.
Not supported by the provided label text excerpts.
Clonazepam is used to treat anxiety disorders.
Not supported by the provided label text excerpts (INDICATIONS AND USAGE section not included in the provided label content).
Clonazepam is used to treat seizures.
Not supported by the provided label text excerpts (INDICATIONS AND USAGE section not included in the provided label content).
Clonazepam is used to treat panic attacks.
Not supported by the provided label text excerpts (INDICATIONS AND USAGE section not included in the provided label content).
Potency refers to the concentration of the active pharmaceutical ingredient (API) in a medication.
Not defined in the provided label excerpts.
In the case of clonazepam, the API is clonazepam hydrochloride.
Partially supported at best; the provided DESCRIPTION excerpt lists strengths of clonazepam but does not explicitly identify the API as clonazepam hydrochloride.
The potency of clonazepam is measured in milligrams (mg) per tablet or capsule.
The provided label excerpt shows tablet strengths (mg) but does not define potency measurement as mg per tablet/capsule.
Aurobindo tests raw materials used to manufacture clonazepam, including clonazepam hydrochloride, to ensure their purity and potency.
No manufacturing/testing/QC details present in the provided label excerpts.
Aurobindo conducts in-process testing during manufacturing to ensure the clonazepam hydrochloride is being incorporated into the tablets at the correct concentration.
No manufacturing in-process testing details present in the provided label excerpts.
Aurobindo conducts final product testing after manufacturing to ensure the clonazepam tablets meet required potency standards.
No manufacturing final product testing details present in the provided label excerpts.
Aurobindo conducts validation studies to ensure the manufacturing process is consistent and that the clonazepam tablets meet required potency standards.
No validation study details present in the provided label excerpts.
Aurobindo uses high-performance liquid chromatography (HPLC) to test the potency of clonazepam.
No analytical method information present in the provided label excerpts.
Aurobindo uses ultraviolet (UV) spectrophotometry to test the potency of clonazepam.
No analytical method information present in the provided label excerpts.
Aurobindo uses titration to test the potency of clonazepam.
No analytical method information present in the provided label excerpts.
Aurobindo's quality control measures are designed to comply with regulatory requirements set by the US Food and Drug Administration (FDA).
No QC/regulatory compliance descriptions present in the provided label excerpts.
Aurobindo's quality control measures are designed to comply with regulatory requirements set by the International Conference on Harmonisation (ICH).
No QC/regulatory compliance descriptions present in the provided label excerpts.
Aurobindo's clonazepam tablets are manufactured in accordance with Good Manufacturing Practice (GMP) guidelines.
No manufacturing compliance statements present in the provided label excerpts.
Contradictions
Important Omissions
Indication/usage statements from the actual INDICATIONS AND USAGE section (not provided), which are necessary to verify claims about anxiety disorders, seizures, and panic attacks.
Importance:
High
Safety Assessment
Potential Patient Risk:
Low
No label-supported dosing, contraindication, boxed warning, or pregnancy/monitoring details were provided in the extracted claims. However, because key indication statements are unverifiable/absent and many manufacturing/QC claims are unsupported, overall label alignment is poor; this is an evidentiary/sourcing risk rather than direct dosing guidance risk.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Non-Aligned
Primary Issue
Majority of extracted claims are absent from the provided label text; remaining strength-related claims are only partially supported due to missing explicit 'clonazepam hydrochloride' API identification and potency-definition support.
Suggested Improvement
Limit claims to what is explicitly present in the provided label excerpts (e.g., tablet strengths and administration instruction). Provide exact label citations/sections for indications, API form, and any manufacturing/testing/QC or analytical method statements, or remove those claims.